Laboratorios Farmacéuticos Rovi SA (0ILL)
LSE
58.35
-0.40 (-0.68%)
Closed
Oct 8, 2026
Day's Range
58.2059.00
52 wk Range
52.4587.50
Financial Statements - 0ILL - Laboratorios Farmacéuticos Rovi SA
Revenue
2.80T▲ 28.0%
Net Income
237.24B▲ 100.0%Net Margin 8.5%
EBITDA
474.50B▲ 52.1%
Free Cash Flow
138.01B▼ 20.0%
Income Statement
| Period Ending | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|
| Sales | 2.80T | 2.18T | 2.44T | 2.72T |
| Cost of Goods | 2.02T | 1.60T | 1.74T | 1.88T |
| Gross Profit | 779.57B | 581.05B | 695.82B | 840.08B |
 Operating Expense | - | - | - | - |
| Operating Income | 318.38B | 169.73B | 257.60B | 399.05B |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 324.56B | 162.77B | 223.11B | 377.47B |
| Income Tax | 92.57B | 46.91B | 62.87B | 106.59B |
| Net Income | 237.24B | 118.61B | 163.68B | 274.65B |
| EPS Basic | 237.97 | 112.43 | 162.93 | 271.81 |
| EPS Diluted | 237.92 | 112.39 | 162.8 | 271.51 |
| Basic Shares Outstanding | 944.15M | 944.90M | 943.77M | 943.46M |
| Diluted Shares Outstanding | 944.15M | 944.90M | 943.77M | 943.46M |
| Ebit | - | - | - | - |
| Ebitda | 474.50B | 312.07B | 382.49B | 534.28B |
| Net Income Continuous Operations | 237.24B | 118.61B | 163.68B | 274.65B |
| Minority Interests | -12.32B | -12.37B | -9.84B | -18.16B |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
